LataMed AI Corp. (OTC: LMED), a development-stage digital health and artificial intelligence technology company, provided shareholders with an update regarding the implementation of its previously announced 5-for-1 forward stock split and the related mandatory share exchange process. As of July 7, 2026, the Company has provided FINRA with all requested information and documentation relating to the corporate action. Based on the current status, management anticipates that the action may become effective within approximately the next week, subject to FINRA's review and final processing.
The forward stock split will be implemented in conjunction with the assignment of a new CUSIP number, 21116R404, which will replace the current CUSIP upon effectiveness. The Company emphasized that shareholders holding shares through a brokerage account in “street name” generally are not required to take any action, as brokerage firms and custodians are expected to process the mandatory exchange automatically through the normal securities settlement process. Similarly, registered book-entry shareholders whose shares are held directly with the transfer agent will have their accounts updated automatically to reflect the post-split share balance and new CUSIP.
For shareholders holding physical stock certificates, the process requires attention. While existing certificates will represent the pre-exchange security and do not need to be surrendered immediately, when a shareholder submits a certificate for transfer, sale, or exchange, it will be processed according to the mandatory exchange procedures. The transfer agent will then issue the appropriate number of post-split shares under the new CUSIP. Additional instructions regarding certificate submission, documentation, and timelines will be provided by the transfer agent as the process moves forward.
Dr. Kevin Rodan Levy, Chief Executive Officer of LataMed AI Corp., stated: “We want to ensure that our shareholders clearly understand how the forward stock split and mandatory exchange process will be implemented. While the vast majority of shareholders are expected to have their shares updated automatically through their brokerage accounts or book-entry holdings, we believe it is important to provide clear guidance regarding the process for shareholders holding physical stock certificates.” He added that management intends to focus on advancing the Company's telemedicine platform and pursuing licensing and commercialization opportunities for its CardioAI, PulmoAI, and NeuroAI artificial intelligence platforms, which are key components of its long-term strategy to build an integrated digital healthcare ecosystem throughout Latin America.
The forward stock split supports the Company's continued corporate development and broader strategic initiatives while facilitating the new CUSIP and updated capital structure. Management believes these steps are important for the Company's growth. Shareholders with questions regarding the exchange process are encouraged to contact their brokerage firm or the Company's transfer agent once detailed instructions become available. Further updates regarding the effective date will be provided as the corporate action progresses.
For additional information, visit https://latamed.ai or review the Company's filings with the U.S. Securities and Exchange Commission at www.sec.gov.
